FUSCC Refractory TNBC Platform Study (FUTURE2.0)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple-negative Breast Cancer
Interventions: DRUG: A1: SHR-A1811|DRUG: A2: SHR-A1811 with Camrelizumab|DRUG: B1: TROP2 ADC|DRUG: B2: TROP2 ADC with Camrelizumab|DRUG: C1: SHR-A1811|DRUG: C2: SHR-A1811 with BP102|DRUG: D1: TROP2 ADC|DRUG: D2: TROP2 ADC with BP102|DRUG: E1: SHR-A1811|DRUG: F1: TROP2 ADC|DRUG: G1: SHR-A1811|DRUG: H1: TROP2 ADC
Sponsor: Fudan University